诺华已同意将其持有的诺华印度有限公司70.68%股份，以144.6亿卢比（约合1.59亿美元）的价格出售 给由WaveRise Investments、ChrysCapital Fund X和Two Infinity Partners组成的投资财团，这一交易正式 结束了诺华于2024年2月启动的针对该上市子公司的战略评估。 早在战略评估启动之前，诺华印度已与本土合作伙伴签署多项分销协议，其中包括与Dr. Reddy's Laboratories Ltd.达成的合作，在印度市场销售Voveran、钙系列产品和Methergine等品牌药品。 此次股份剥离调整了诺华印度的所有权结构，同时诺华保留了在印度市场的基础设施与研发布局，维持 其在当地的业务根基。 市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 作者：观察君 诺华印度有限公司主要负责在印度市场销售处方药、仿制药和非处方药。此次交易完成后，该公司将在 新的多数股权所有者领导下推进业务发展。作为交易的配套环节，收购财团同步发起公开要约，拟以每 股860.84卢比的价格，收购诺华印度至多26%的股份，该要约对应价值约55.2 ...

Core Viewpoint - Novartis AG is selling its entire 70.68% stake in Novartis India for approximately Rs 1,446 crore to a consortium including WaveRise Investments, ChrysCapital, and Two Infinity Partners, with an open offer for an additional 26% stake from public shareholders at Rs 860.64 per share, representing a 3.6% premium to the previous closing price [8][6]. Group 1: Acquisition Details - The consortium has signed an agreement to acquire Novartis AG's stake at Rs 860.64 per share, which is in accordance with SAST regulations [8][6]. - The total consideration payable under the open offer, assuming full acceptance, will be Rs 552.5 crore [8][6]. - If the entire 26% shareholding is tendered, WaveRise will own 72.78% of equity, ChrysCapital Fund X will own 17.33%, and Two Infinity Partners will hold 6.57% [4][8]. Group 2: Ownership Scenarios - In the event that no shares are tendered under the open offer, WaveRise will still have a majority stake of 56.45%, while ChrysCapital's fund will own 10.32% and Two Infinity Partners will have 3.91% [5][8]. - The open offer is a mandatory requirement under SEBI regulations due to the acquisition of a substantial number of equity shares and control over the target company [6][8]. Group 3: Future Plans - After the acquisition, the new owners plan to change the company's name, pending regulatory and corporate approvals [2][8]. - This divestment follows Novartis's strategic review of its stake in Novartis India, which began two years prior [6][8].

Novartis AG has agreed to sell a majority stake in its listed Indian unit, marking the culmination of a strategic review announced two years ago.The Swiss drugmaker will sell its 70.68% stake in Novartis India Ltd. to a consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners for ₹1,446 crore ($159 million), according to a statement to the exchanges.The buyers have also launched an open offer to acquire up to 26% of Novartis India at ₹860.84 a share, valuing the offer at about ₹552 ...